ClinicalTrials.gg
TerminatedNCT03379207ImPACTUpdated Nov 24, 2025

Innate Immune Response During Community Acquired Pneumonia

An observational study in Community-acquired Pneumonia, Acute Respiratory Distress Syndrome and Innate Immunity, sponsored by University Hospital, Tours. Terminated at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by University Hospital, Tours · Observational

Why this study was terminated
A new project has been started. It extends ImPACT, with more financial resources and with scientific questions that have evolved.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
258
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-14

Among 40 studies in Community-Acquired Pneumonia with a site in France — 11 open to participants now, 11 under way, 5 of them phase 3. Community-Acquired Pneumonia · France.

Enrollment
9th of 14
258 · median 365
Started
2018
with 1 other
Observational
14 of 40
2 open now
Registered
17th of 40
by date
Lead sponsor
3 of 40
University Hospital, Tours

Among the 40 studies in Community-Acquired Pneumonia with a site in France, this one is the 9th largest by enrollment of the 14 observational ones that give a count, is one of 2 that started in 2018, is one of 14 observational ones, and was the 17th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 78 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

11 of the 40 studies in Community-Acquired Pneumonia with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Community-Acquired Pneumonia with a site in France, or all of them as a file.
02

Study summary

Community acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. Despite recent improvement in acute management (specifically for administration of antibiotics) many severe presentations of pneumonia worsen, progressing to Acute Respiratory Distress Syndrome (ARDS), a clinical entity with 40% hospital mortality.

Dysregulation of immune response is thought to be largely implicated in severe pneumonia progressing to ARDS. Notably, experimental studies have recently suggested the implication of non-conventional T lymphocytes and innate cells in this immunopathology. However, no data are available in Humans in clinical settings.

This study aims to explore the role of non-conventional T cells in pneumonia and ARDS, in participants. For this purpose, 100 participants admitted to Intensive Care Unit (ICU) with a diagnosis of CAP will be included, and 50 "control" participants with no pneumonia nor shock. Presence and functionality of non-conventional T cells and innate cells will be explored using flow-cytometry and ex-vivo stimulation, alongside with cytokines productions. These analyses are conducted in the blood, and, for invasively ventilated participants, in tracheal aspirates or broncho-alveolar fluids if available. For each participants included, the analyses are conducted at different time-points during ICU stay: inclusion, day 3, day 8 and day 15. Moreover, participants with ARDS, for whom a post-ICU follow-up program is normally established after discharge, will have blood analysis from blood samples taken during the follow-up visit up to 8 months after inclusion.

Immunophenotypage and functionality of non-conventional T cells and innate cells will be compared to clinical parameters and their evolution, between "CAP" participants and "Control" participants", and for each participants, according to the different time-point of analysis, in order to better understand dynamic of innate immunity during pneumonia and ARDS.

Read the detailed description

- Clinical and scientific background:

Community acquired pneumonia is a major cause of morbidity and mortality worldwide. Despite recent improvement in acute management (specifically for administration of antibiotics), severe pneumonia can worsen and ultimately progressing to Acute Respiratory Distress Syndrome (ARDS), a clinical entity with an inacceptable 40% hospital mortality. From a pathophysiological point of view, ARDS is characterized by a deregulation of pulmonary inflammation initially triggered by the local aggression, which is, in two-third of the cases, a pneumonia. Alteration of tissue repair is another major characteristic of this entity. So far, the scientific knowledge on this pathophysiology did not translate into specific therapy that could modulate efficiently the inflammatory response and to control the progression from pneumonia to ARDS, and/or to improve tissue repair. Thus, a complete reconsideration of the pathophysiological mechanisms is mandatory. Recent progresses in mucosal biology and innate immunity give interesting new opportunities. Specifically, recently discovered unconventional T cells have shown to be major actors in shaping and modulating early immune responses in the lung mucosa during microbial aggressions and for secondary tissue repair. However, these evidences are limited to pre-clinical models. In many other human diseases (oncology, immune diseases), these sub-populations are already being explored as potential targets for immune therapies.

- Objective of the study:

The aim of this study is to explore potential implications of unconventional T cells during human severe pneumonia and ARDS.

This translational study will complement experimental approaches currently undertaken in the laboratory exploring the role of unconventional T cells in murine models of severe pneumonia and ARDS.

- Design:

This is a prospective single-center study including participants admitted in Intensive Care Department of the university hospital of Tours for community-acquired pneumonia. Given the exploratory nature of the study, we designed a "control" group of participants admitted to ICU without evident signs of pneumonia and shock.

Number of participants: 300 for "pneumonia" group, and 50 for "control" group

- Interventions and analysis:

Blood samples will be collected at inclusion, day 3, 8 and 15 during patient's stay in ICU. For mechanically ventilated participants, tracheal aspirates will be also collected at the same timing. If available, broncho-alveolar lavages will be also collected. If ARDS or Ventilator Associated Pneumonia (VAP) are subsequently diagnosed, supplemental blood and tracheal aspirates samples will be collected.

Blood samples and airway fluid samples will be treated to perform flow cytometry analysis for immunophenotypage (cellular content). In some cases, intra-cellular staining will be performed to assess cytokine production and/or transcription factor expression. Functions of unconventional T cells will also be performed after ex vivo stimulation on purified population (cell sorting). Cytokine level sand transcriptomic analyses will also be performed on blood samples.

Clinical characteristics (including respiratory parameters, blood gas, organ dysfunctions, survival at day 28 and day 90) will also be collected. Thus, frequency, activation status and functions of unconventional T cells will be dynamically analyzed in regard of clinical evolution within-individuals and across pneumonia vs control groups. A particular focus will be made on respiratory parameters (ventilation mode, and for participants with ARDS, P/F ratio, driving pressure), organ dysfunctions (as measured by SOFA score), and microbial documentation of the pneumonia.

Moreover, participants treated for ARDS are usually followed in a post-ICU follow-up clinic program in the ICU where the research is conducted. Thus, investigators will perform analysis of the unconventional T cell compartment (blood samples) in the participants firstly enrolled in the study. This will allow exploration of long-term imprinting on the innate immune response after the initial trigger.

03

Conditions studied

  • Community-acquired Pneumonia
  • Acute Respiratory Distress Syndrome
  • Innate Immunity

Keywords

  • Community-acquired Pneumonia
  • Acute Respiratory Distress Syndrome
  • Innate Immunity
  • Non Conventional T Lymphocytes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants admitted to the Intensive Care Unit of the University Hospital of Tours or University Hospital of Limoges (France) with an initial diagnosis of Community Acquired Pneumonia, or participants admitted without diagnosis of pneumonia or shock and for whom invasive mechanical ventilation is required.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

"Pneumonia" group:

  • Admission to the Intensive Care Units or Pneumonia service of Tours University Hospital or Intensive Care Unit or Limoges University Hospital
  • Initial diagnosis of acute community-acquired pneumonia suggested by the presence of a cough, dirty sputum, chest pain and / or dyspnea (at least two criteria required), associated with the presence of a radiological or CT infiltrate initially
  • Patient for whom it is not envisaged, a priori, to limit treatment within 5 days following inclusion, for ethical reasons, due to age and advanced comorbidities, and / or a level of severity beyond all therapeutic possibilities.
  • Diagnosis of pneumonia done within 48 hours after admission to the hospital
  • Participant admitted to the hospital for less than 8 days

"Control" group:

  • Admission to the Intensive Care Units of the University Hospital of Tours or Limoges University Hospital
  • Use of invasive mechanical ventilation for less than 48 hours
  • Predictable duration of invasive mechanical ventilation> 48h
  • Participant admitted to the hospital for less than 8 days
  • Absence of pneumonia criteria (according to the criteria defined for the "Pneumonia" participant group)
  • Absence shock (defined by the need for vasopressor despite volume expansion ≥30mL/kg, associated with a blood lactate level ≥ 2mmol / L
  • Patient for whom it is not envisaged, a priori, to limit treatment within 5 days following inclusion, for ethical reasons, due to age and advanced comorbidities, and / or a level of severity beyond all therapeutic possibilities.

Exclusion criteria

Exclusion Criteria:

  • Participant under protection
  • Pregnant or lactating women
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
258 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • "Community Acquired Pneumonia" group

    Participants admitted to Intensive Care Unit (ICU) of University Hospital of Tours (France) for Community Acquired Pneumonia. Interventions: * Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 1, 7, and every week during ICU stay Tracheal Aspirates for research purpose: only for mechanically ventilated participants, at inclusion, day 1, 7, and and every week during ICU stay * Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)

    Other: Blood samples · Other: Tracheal Aspirates · Other: Surplus of Broncho-alveolar lavage fluid

  • "Control" group

    Participants admitted to Intensive Care Unit of University Hospital of Tours (France) for whom invasive mechanical ventilation is required for an estimated duration of at least 48h, without diagnosis of pneumonia or shock. Interventions: * Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 3, 8, and 15 during ICU stay Tracheal Aspirates for research purpose: at inclusion, day 3, 8, and 15 during invasive mechanical ventilation period, * Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)

    Other: Blood samples · Other: Tracheal Aspirates · Other: Surplus of Broncho-alveolar lavage fluid

Interventions

  • OtherBlood samples

    Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose

  • OtherTracheal Aspirates

    Only for mechanically ventilated participants.

  • OtherSurplus of Broncho-alveolar lavage fluid

    Only if performed for diagnosis purpose by the treating investigator : indication left at his discretion

06

What researchers measure

Primary outcomes

  1. Blood level of Non-Conventional T Lymphocytes (expressed as % CD3+ lymphocytes)

    Time frame: 8 Months

  2. Airway level of Non-Conventional T Lymphocytes (expressed as % CD3+ lymphocytes)

    Time frame: 8 Months

  3. Blood level of inflammatory cytokines

    Time frame: 8 months

  4. Airway level of inflammatory cytokines

    Time frame: 8 months

Secondary outcomes

  1. Blood level of Conventional T Lymphocytes (expressed as % CD3+ lymphocytes)

    Time frame: 8 months

  2. Airway level of Conventional T Lymphocytes (expressed as % CD3+ lymphocytes)

    Time frame: 8 months

  3. Metabolic signature of non-conventional T lymphocytes

    Time frame: 8 months

  4. Transcriptomic signature of non-conventional T lymphocytes

    Time frame: 8 Months

  5. Blood level of Innate Cells (expressed as % CD45+ lymphocytes)

    Time frame: 8 months

  6. AIrway level of Innate Cells (expressed as % CD45+ lymphocytes)

    Time frame: 8 months

07

Study locations

3 sites
  • University Hospitakl of TOURS Département of Pneumonia
    Tours, 37044, France
  • University Hospital -Bretonneau - Intensive Care
    Tours, 37044, France
  • University Hospital of Tours; INSERM CIC 1415
    Tours, 37044, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Jun 2025, 88 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2017
First posted
Dec 20, 2017
StartActual
Jan 10, 2018
Primary completionActual
Jun 4, 2025
CompletionActual
Jun 4, 2025
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03379207
Responsible party
Sponsor
First posted
Dec 20, 2017
Start date
Jan 10, 2018
Primary completion
Jun 4, 2025
Completion
Jun 4, 2025
Last update
Nov 24, 2025

Study contacts

Youenn JOUAN, MD-PHD
study director · University of TOURS-INSERM U1100

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion